VBI Vaccines, Inc. (VBIV) financial statements (2020 and earlier)

Company profile

Business Address 222 THIRD STREET
CAMBRIDGE, MA 02142
State of Incorp. BC
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments44596832
Cash and cash equivalents44596832
Receivables0000
Inventory, net of allowances, customer advances and progress billings1111
Inventory1111
Prepaid expense111 
Other current assets0111
Total current assets:47627034
Noncurrent Assets
Operating lease, right-of-use asset1
Property, plant and equipment10922
Intangible assets, net (including goodwill)63677268
Goodwill2898
Intangible assets, net (excluding goodwill)61586360
Deposits noncurrent assets   0
Other noncurrent assets1110
Total noncurrent assets:75767570
TOTAL ASSETS:122138146105
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1622
Accounts payable1622
Deferred revenue1
Debt1   
Due to related parties1512 
Deferred revenue and credits 0
Contract with customer, liability2
Other liabilities1214106
Total current liabilities:3023138
Noncurrent Liabilities
Long-term debt and lease obligation1  12
Long-term debt, excluding current maturities   12
Operating lease, liability1
Liabilities, other than long-term debt316121
Deferred revenue and credits11
Deferred revenue3
Contract with customer, liability3
Deferred tax liabilities, net  0
Due to related parties 1312 
Other undisclosed noncurrent liabilities0000
Total noncurrent liabilities:4161313
Total liabilities:34392621
Stockholders' equity
Stockholders' equity attributable to parent889812084
Common stock285246202133
Additional paid in capital66636159
Accumulated other comprehensive income (loss)(1)(4)1(3)
Accumulated deficit(262)(208)(144)(105)
Total stockholders' equity:889812084
TOTAL LIABILITIES AND EQUITY:122138146105

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues2311
Cost of revenue(8)(5)(5)(4)
Gross profit:(6)(1)(4)(3)
Operating expenses(55)(64)(38)(25)
Other undisclosed operating income8554
Operating loss:(52)(60)(37)(25)
Nonoperating income (expense)
(Foreign Currency Transaction Gain (Loss), before Tax)
(0)(1)10
Interest and debt expense(2)(3)3(0)
Loss from continuing operations before equity method investments, income taxes:(55)(64)(34)(25)
Other undisclosed loss from continuing operations before income taxes  (6) 
Loss from continuing operations before income taxes:(55)(64)(39)(25)
Income tax benefit  02
Net loss available to common stockholders, diluted:(55)(64)(39)(23)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(55)(64)(39)(23)
Other comprehensive income (loss) (5)4(2)
Comprehensive loss:(55)(69)(35)(25)
Other undisclosed comprehensive income, net of tax, attributable to parent3   
Comprehensive loss, net of tax, attributable to parent:(51)(69)(35)(25)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: